Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and sells medicines globally for various diseases. The company develops potential treatments for eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases, as well as cancer and hematologic conditions. Its product portfolio includes EYLEA injections for wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity. It also offers Dupixent injection for atopic dermatitis and asthma, Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma, Praluent injection for heterozygous familial hypercholesterolemia (HoFH), and Kevzara solution for rheumatoid arthritis. Regeneron has a license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA. It collaborates with Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for eye and central nervous system diseases. The company also works with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development focused on neurological and muscular diseases. Regeneron has an agreement with Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor. Additionally, it collaborates with Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency, and with Telix Pharmaceuticals Limited for radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.